OncoMatch/Clinical Trials/NCT06702033
The Minimalist Trial-2
Is NCT06702033 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Cisplatin for hpv-related oropharynx squamous cell carcinoma.
Treatment: Cisplatin — Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer. Oropharynx SCC (OPSCC) is a common sub-type of HNSCC. Each year, 16,000 new cases of OPSCC are diagnosed in the USA. Most cases of OPSCC (\>90%) are caused by the human papillomavirus (HPV) and are often cured with current therapy. However, patients treated with surgery followed by postoperative adjuvant chemotherapy and radiation therapy (POA(C)RT) still experience substantial morbidity. In this highly curable disease, current clinical research interest is focused on investigation of de-escalated therapy, with the goal to reduce treatment-related adverse events (AEs) while maintaining a low recurrence rate. In this study, patients with HPV-related OPSCC will undergo resection of the primary tumor site and involved/at-risk regional neck nodes. Based on the pathology report, patients will be assigned to: * Arm 1 (de-POACRT-42 Gy) * Arm 2A (de-POART-42 Gy) * Arm 2B (de-POART-37.8 Gy) * Arm 2C (de-POACRT-30 Gy). All patients with high-risk pathology will be assigned to Arm 1 whereas patients with intermediate-risk pathology will be randomized (1:1:1) to Arm 2A, Arm 2B, or Arm 2C. Patients with highest-risk pathology and low-risk pathology will be removed from the trial after surgery and will be advised to pursue standard of care options.
Check if I qualifyExtracted eligibility criteria
Biomarker criteria
Required: HPV high-risk HPV positive
HPV-related may be defined by p16 IHC stain and/or HPV-High Risk RNA ISH/HPV DNA genotyping by PCR, using standard definitions of positive and negative test results
Disease stage
Required: Stage I, II
Excluded: Stage T1N0M0, T2N0M0
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Blood counts
ANC ≥ 1.0 K/cumm; Platelet count ≥100 K/cumm
Kidney function
Creatinine clearance ≥ 50 mL/min
Adequate organ and marrow function defined as: Creatinine clearance ≥ 50 mL/min. ANC ≥ 1.0 K/cumm. Platelet count ≥100 K/cumm.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Washington University School of Medicine · St Louis, Missouri
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify